BTLA Human
Sf9, Insect cells.
B- and T-lymphocyte attenuator, B- and T-lymphocyte-associated protein, CD272, B And T Lymphocyte Associated, B- And T-Lymphocyte-Associated Protein, B- And T, Lymphocyte Attenuator, CD272 Antigen, BTLA1.
Sterile filtered colorless solution.
Greater than 90.0% as determined by SDS-PAGE.
Description
BTLA produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 136 amino acids (31-157 a.a.) and having a molecular mass of 15.7kDa (Molecular size on SDS-PAGE will appear at approximately 18-28kDa).
BTLA is expressed with a 9 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
BTLA, short for B And T Lymphocyte Associated, acts as an inhibitory molecule belonging to the Ig superfamily. This type 1 transmembrane glycoprotein is classified under the CD28 family of T cell costimulatory molecules. Functionally similar to CTLA-4 and PD-1, BTLA serves as the third inhibitory receptor on T lymphocytes. Additionally, it acts as a ligand for TNFRSF14, a member of the TNF (receptor) superfamily, and HVEM. Notably, BTLA-HVEM complexes exhibit a regulatory effect on T-cell immune responses, suppressing their activity.
Produced using Sf9 Insect cells, BTLA is a single, glycosylated polypeptide chain comprising 136 amino acids (specifically, amino acids 31 to 157). It possesses a molecular mass of 15.7 kDa. However, it's important to note that on SDS-PAGE, the molecular size appears to be between 18 and 28 kDa. The BTLA protein is engineered with a 9 amino acid His tag at the C-terminus, and its purification is carried out using proprietary chromatographic techniques.
The product appears as a colorless solution that has been sterilized through filtration.
The BTLA protein solution is provided at a concentration of 0.5 mg/ml. It is prepared in a solution of Phosphate Buffered Saline (pH 7.4) containing 10% glycerol.
For short-term storage (up to 2-4 weeks), the product can be kept at a temperature of 4°C. For extended storage, it is recommended to freeze the product at -20°C. Adding a carrier protein, such as HSA or BSA, at a concentration of 0.1% is advisable for long-term storage. It is important to minimize repeated freeze-thaw cycles to maintain product integrity.
Analysis by SDS-PAGE indicates a purity exceeding 90%.
B- and T-lymphocyte attenuator, B- and T-lymphocyte-associated protein, CD272, B And T Lymphocyte Associated, B- And T-Lymphocyte-Associated Protein, B- And T, Lymphocyte Attenuator, CD272 Antigen, BTLA1.
Sf9, Insect cells.
ADPKESCDVQ LYIKRQSEHS ILAGDPFELE CPVKYCANRP HVTWCKLNGT TCVKLEDRQT SWKEEKNISF FILHFEPVLP NDNGSYRCSA NFQSNLIESH STTLYVTDVK SASERPSKDE MASRPWLLYS HHHHHH.
Product Science Overview
B and T Lymphocyte Attenuator (BTLA), also known as CD272, is a type I transmembrane glycoprotein that belongs to the CD28 family of T cell costimulatory molecules . It plays a crucial role in the immune system by regulating the activation and inhibition of lymphocytes, which are essential for the body’s immune response.
BTLA is a 35 kDa protein that consists of three main domains:
- Extracellular Domain (ECD): This domain contains 127 amino acids and is responsible for interacting with other molecules on the surface of cells.
- Transmembrane Sequence: A 21 amino acid sequence that anchors the protein in the cell membrane.
- Cytoplasmic Domain: Comprising 111 amino acids, this domain is involved in transmitting signals inside the cell .
BTLA functions as an inhibitory receptor on lymphocytes, negatively regulating antigen receptor signaling. It interacts with TNFRSF14 (also known as HVEM) either in cis (on the same cell) or in trans (on other cells). These interactions play a role in maintaining the resting state of naive T cells and providing survival signals to effector T cells during the adaptive immune response .
Recombinant human BTLA is produced using human embryonic kidney (HEK293) cells. The recombinant protein typically includes a C-terminal 6-His tag for purification purposes. It is used in various research applications, including studying the immune response and developing potential therapeutic interventions .
BTLA has been associated with several diseases, including hematologic cancers and autoimmune disorders like rheumatoid arthritis. Polymorphisms in the BTLA gene can increase the risk of these conditions . Understanding the role of BTLA in the immune system can help in developing targeted therapies for these diseases.
Recombinant human BTLA is used in various experimental setups, such as:
